Capital World Investors Grows Stock Holdings in Amgen Inc. $AMGN

Capital World Investors increased its position in Amgen Inc. (NASDAQ:AMGN) by 11.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 18,795,474 shares of the medical research company’s stock after acquiring an additional 1,935,876 shares during the period. Amgen comprises about 0.7% of Capital World Investors’ investment portfolio, making the stock its 29th biggest holding. Capital World Investors’ holdings in Amgen were worth $5,303,578,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in AMGN. Vanguard Group Inc. boosted its stake in shares of Amgen by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock worth $15,204,047,000 after acquiring an additional 165,281 shares during the last quarter. State Street Corp increased its holdings in Amgen by 0.6% in the 2nd quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock worth $8,196,775,000 after acquiring an additional 177,035 shares in the last quarter. Capital International Investors lifted its holdings in Amgen by 1.5% during the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock valued at $5,414,296,000 after purchasing an additional 282,219 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Amgen by 2.3% during the 2nd quarter. Geode Capital Management LLC now owns 13,018,617 shares of the medical research company’s stock valued at $3,619,489,000 after buying an additional 291,271 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Amgen by 5.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock worth $3,600,043,000 after buying an additional 687,735 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

NASDAQ AMGN opened at $376.97 on Tuesday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The firm has a market capitalization of $203.21 billion, a P/E ratio of 26.49, a P/E/G ratio of 3.67 and a beta of 0.45. The firm’s fifty day simple moving average is $354.21 and its two-hundred day simple moving average is $323.38.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s revenue was up 8.6% compared to the same quarter last year. During the same period in the previous year, the business posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Analysts Set New Price Targets

AMGN has been the topic of a number of research analyst reports. Erste Group Bank raised Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. Guggenheim increased their target price on Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Wall Street Zen downgraded shares of Amgen from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. TD Cowen reiterated a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Finally, Cantor Fitzgerald increased their target price on shares of Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Amgen has an average rating of “Hold” and an average price target of $354.17.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.